Four years after EU approval, NICE finally backs Revlimid use in certain first-line multiple myeloma patients
Four years after the European Commission sanctioned the use of Celgene’s flagship Revlimid to treat adults with previously-untreated multiple myeloma who are not eligible …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
